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Probing the substrate speciﬁcity of Trypanosoma
brucei GlcNAc-PI de-N-acetylase with synthetic
substrate analogues†
Amy S. Capes,‡ Arthur Crossman,‡ Michael D. Urbaniak, Sophie H. Gilbert,
Michael A. J. Ferguson* and Ian H. Gilbert*
A series of synthetic analogues of 1-D-(2-amino-2-deoxy-α-D-glucopyranosyl)-myo-inositol 1-(1,2-di-
O-hexadecanoyl-sn-glycerol 3-phosphate), consisting of 7 variants of either the D-myo-inositol, D-GlcpN
or the phospholipid components, were prepared and tested as substrates and inhibitors of GlcNAc-PI de-
N-acetylase, a genetically validated drug target enzyme responsible for the second step in the glycosyl-
phosphatidylinositol (GPI) biosynthetic pathway of Trypanosoma brucei. The D-myo-inositol in the
physiological substrate was successfully replaced by cyclohexanediol and is still a substrate for T. brucei
GlcNAc-PI de-N-acetylase. However, this compound became sensitive to the stereochemistry of the gly-
coside linkage (the β-anomer was neither substrate or inhibitor) and the structure of the lipid moiety (the
hexadecyl derivatives were inhibitors). Chemistry was successfully developed to replace the phosphate
with a sulphonamide, but the compound was neither a substrate or an inhibitor, conﬁrming the impor-
tance of the phosphate for molecular recognition. We also replaced the glucosamine by an acyclic ana-
logue, but this also was inactive, both as a substrate and inhibitor. These ﬁndings add signiﬁcantly to our
understanding of substrate and inhibitor binding to the GlcNAc-PI de-N-acetylase enzyme and will have a
bearing on the design of future inhibitors.
Introduction
The enzymes of the glycosylphosphatidylinositol (GPI) bio-
synthetic pathway are located in the endoplasmic reticulum,
contain between one and thirteen predicted trans-membrane
domains and are mostly present as components of multi-
subunit complexes.1 No high-resolution structural data are
available on any of these enzymes and our research group has
been probing the specificities of several of the enzymes in the
GPI pathway of the protozoan parasite Trypanosoma brucei, the
causative agent of African sleeping sickness in humans and
the related disease Nagana in cattle, using synthetic substrate
analogues in vitro.2–8 One of the key enzymes of interest is an
amidase, the GlcNAc-PI de-N-acetylase (EC 3.5.1.89) that de-
N-acetylates 1-D-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-myo-
inositol 1-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) (1,
α-D-GlcpNAc-PI) to 1-D-(2-amino-2-deoxy-α-D-glucopyranosyl)-
myo-inositol 1-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate)
(2, α-D-GlcpN-PI), Fig. 1.
This enzyme catalyses the second step in the T. brucei GPI
biosynthetic pathway, which is a prerequisite for all sub-
sequent steps in the pathway.9 In earlier studies, we showed
that T. brucei GlcNAc-PI de-N-acetylase is a zinc-dependent
metalloenzyme10 and demonstrated, by construction of a con-
dition-null mutant cell line, that it is essential for the blood-
stream form of the parasite and, therefore, a genetically
validated drug target.11 Previous studies with other substrate
analogues showed that the phosphate, 2′-NHAc and 3′-OH
groups of the natural substrate α-D-GlcpNAc-PI (1) are critical
for recognition by the T. brucei GlcNAc-PI de-N-acetylase.2–4 In
contrast, the diacylglycerol moiety is not strictly required and
may be eﬃciently replaced with an octadecyl chain,4 as shown
in analogues 3 and 4. In the case of the T. brucei enzyme, we
had hypothesised that one or more of the inositol 2, 3, 4 and
5-OH groups is/are not required.2–4 We came to this hypothesis
from the ability of the enzyme to recognise and process both
α-D-GlcpNAc-[L]-PI (5) and β-D-GlcpNAc-PI (6). Molecular
dynamics simulations, showed that α and β anomers can
adopt conformations in which the phosphate, the 2′-amide
†Electronic supplementary information (ESI) available: Additional experimental
procedures and characterisation data for the β-anomers 8 and 10 plus 1H and
13C NMR spectra of all the compounds. See DOI: 10.1039/c3ob42164c
‡These authors contributed equally to the work.
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and the 3′-OH overlay. Given the 2′-amide is where the reaction
occurs, and evidence suggests that the 3′-OH and phosphate
are important for recognition of the substrate with the
enzyme, these conformations are likely to be the active
enzyme-bound conformations. In these conformations the ino-
sitol 2-, 3-, 4- and 5-hydroxyls are in diﬀerent orientations for
the two α and β anomers, implying the hydroxyls are not criti-
cal for interaction with the enzyme. Further evidence was
obtained from a compound in which the inositol 2-hydroxyl
was alkylated. This was also a substrate for the T. brucei
enzyme. One of the goals of the study described in this paper
was to investigate the hypothesis that the inositol 2, 3, 4 and
5-OH groups are not required.
Bearing in mind these key structural features, we have syn-
thesised a variety of analogues to further probe the require-
ments for substrate recognition by the T. brucei GlcNAc-PI de-
N-acetylase and, specifically, to test:
1. The hypothesis that the inositol 2, 3, 4 and 5-OH groups
are not required for enzyme recognition, a series of pseudodi-
saccharides (7–10, Fig. 2) containing a cyclohexanediol moiety
in place of the inositol aglycone were prepared.
2. Whether the phosphate group can be replaced by more
cell-permeable sulphonamide isosteres,12 compounds 11 and
12 (Fig. 2) were prepared.
3. Whether, given the essentiality of the 2′-NHR and 3′-OH
groups but non-essentiality of the 4′- and 6′-OH groups for
substrate recognition, the glucosamine residue might be sim-
plified to a simple acyclic structure, as in compound 13.
The N-acetylated derivatives of the above analogues
required for biological studies with the de-N-acetylase were
prepared from the corresponding amines by standard pro-
cedures.13 All the analogues were examined for their recog-
nition and processing by the T. brucei GlcNAc-PI de-N-
acetylase.
Results and discussion
Synthesis of analogues 7–13
The synthesis of the required α and β-glucosaminyl (1′ → 1)
cyclohexanediol building blocks 16 and 17, respectively, began
by reacting the known14 trichloroacetimidate 14 and the com-
mercially available 1R,2R-trans-cyclohexanediol 15, Scheme 1,
with a catalytic amount of trimethylsilyl trifluoromethanesul-
fonate (TMSOTf). The separation of anomers was achievable at
this stage and these anomers were vital in providing the gluco-
samine-phosphodiester target analogues discussed herein. For
the sake of brevity, we have chosen to describe in the main text
the formation of the α-anomers, while details for the corres-
ponding β-anomers appears in the ESI.† Therefore, the pseu-
dodisaccharide 16 was coupled to the hydrogen phosphonate
18,15 and the ensuing mixture of diastereoisomeric
Fig. 1 Some previously prepared GPI analogues.
Fig. 2 Target molecules.
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phosphonic diesters, was oxidised with iodine in pyridine–
water16 to give the corresponding phosphodiester 19. The
diester was transformed into the triol 20 after conventional
O-deacylation of the latter compound with 0.05 M methanolic
NaOMe in CH2Cl2–MeOH.
Our first attempt at hydrogenolysis of the triethylammo-
nium (TEA) salt 20 over Pd(OH)2/C gave, surprisingly, the alkyl
alcohol secondary amine 21. Initially, the azide of 20 was
reduced to the primary amine, however, if there are peroxides
present in the THF then the formation of THF hydroperoxide
is, apparently, possible which could then lead to an amine–
THF coupling via a free-radical-based mechanism.17 This inter-
mediate is susceptible to a Pd-mediated THF ring opening
reaction that gives an imine which is then further hydrogen-
ated to an aminobutanol.17 Consequently, after purchasing a
fresh bottle of anhydrous stabilised THF, the second hydro-
genolysis attempt at 20→ 7 proceeded without incident.
The preparation of the dipalmitoyl glycerol pseudodisac-
charide 9 was accomplished from the triacetate 16, Scheme 2.
However, the acetate protecting groups in 16 are unsuitable
because if they were left in place and removed by base at the
final step of the synthesis, then those requisite esters of
the lipid fragment would likewise be saponified. Therefore,
the acetates of 16 needed to be swapped to a more appropriate
protecting group but first, the temporary tert-butyldimethylsilyl
(TBDMS) protection of the 2-OH, 16 → 22, was performed and
Scheme 1 Synthesis of 7.
Scheme 2 Synthesis of 9.
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then followed by conventional O-deacylation, as previously
described for 19→ 20, furnished the triol 23.
The benzyl group was chosen as the 3′, 4′ and 6′-OH protect-
ing group because, from our past experiences synthesising GPI
analogues, the benzyl group has been a very reliable protecting
group via ease of installation and removal. Thus, the triol 23
was benzylated with benzyl bromide in the presence of NaH,
as the base, to aﬀord compound 24. We next turned our atten-
tion towards the reduction of the azide in 24 and because of
the issues with Pd(OH)2 catalysed reduction in the presence of
peroxidic THF discussed earlier, we chose to reduce the azide
via the Staudinger reaction18 to give the amine 25 which was
subsequently tert-butyl carbamate (Boc) protected to furnish
26. Desilylation of 26 using HF–pyridine conditions aﬀorded
the alcohol 27. The known hydrogen phosphonate 2819 was
coupled, as already described, to the 2-OH of 27 which, after
oxidation, was isolated and characterised as the TEA salt 29.
Hydrogenolysis of 29 over Pd(OH)2/C gave the Boc protected
derivative 30 and subsequent cleavage of the Boc group pro-
duced the deprotected target analogue 9.
Sulphonamides are potential isosteres for the phosphate
group; they have the same tetrahedral shape and polar oxygen
atoms. The synthesis of the sulphonamides 11 and 12,
Scheme 3, was accomplished by reacting commercially
available 1R,2R-1-amino-2-benzyloxycyclohexane 31 with
1-octadecanesulfonyl chloride in the presence of triethylamine
and CH2Cl2 to give the benzyl derivative 32. The benzyl group
was removed by hydrogenolysis over Pd(OH)2/C to furnish the
alcohol 33. Coupling of 33 with the known trichloroacet-
imidate 3420 resulted in an inseparable mixture of the α,β-ano-
mers 35 in the ratio of ∼1 : 1, as determined by 1H NMR
spectroscopy. Finally, hydrogenolysis of the aforementioned
anomers 35 over Pd(OH)2/C and subsequent silica gel column
chromatography (9 : 1 CH2Cl2–MeOH) gave first the β-anomer
11 and then the α-anomer 12.
We were also interested in seeing if we could replace the
glucose ring with an acyclic moiety. From our knowledge of
the SAR, retaining the 2-amino and 3-hydroxy groups are
important for activity. The synthesis of the amino-phosphate
13, Scheme 4, began by epoxide ring-opening of cyclohexene
oxide 36 with p-methoxybenzyl alcohol (PMBOH), using
Cu(BF4)2·nH2O as a catalyst
21 to give the known racemic PMB
monoprotected cyclohexanediol22 contaminated with
unreacted PMBOH. Chromatographic separation of this PMB
cyclohexyl derivative from the excess of PMBOH was not
achievable, in our hands, and so the entire PMB reaction
residue was acetylated with acetic anhydride in the presence of
pyridine and a catalytic amount of 4-(dimethylamino)pyridine
DMAP to furnish the acetate 37, which was easily separated
from the acetate of p-methoxybenzyl alcohol by silica gel
column chromatography.23 After deacetylation, the resulting
alcohol22 residue was alkylated using sodium hydride and allyl
bromide to give the allyl derivative 38. The epoxide 39 was pre-
pared upon reacting 38 with 3-chloroperbenzoic acid (mCPBA),
and the subsequent hydrolysis of epoxide 39 with DMSO, H2O
and a catalytic amount of KOH,24 worked smoothly to furnish
diol 40. The primary alcohol of 40 was protected using tert-
butyl(chloro)diphenylsilane (TBDPSCl) and DMAP to give com-
pound 41. The azido group of 43 was satisfactorily installed
(51% yield over two steps) via the mesylate 42 obtained by
reacting the secondary alcohol 41 with methanesulfonyl chlor-
ide in the presence of pyridine, followed by treatment of 42
with sodium azide under forcing conditions. The crude mesy-
late 42 was used directly in the displacement reaction but a
small portion of 42 was purified for a full characterisation of
this intermediate. The p-methoxybenzyl protecting group of 43
was removed with mild acid to give alcohol 44 and then it was
phosphorylated, as previously described, to give the phospho-
ric diester 45. Thereafter, the removal of the silyl protecting
group of 45 with 1.0 M tetrabutylammonium fluoride (TBAF)
in THF proceeded smoothly to give 46 which, after hydrogeno-
lysis over Pd(OH)2/C, provided the TEA salt 13.
Biological results
Substrate analogues
The ability of the T. brucei GlcNAc-PI de-N-acetylase to recog-
nise and process the synthetic pseudodisaccharides 7–13 was
tested in T. brucei cell-free system using an LC-MS/MS
Scheme 3 Synthesis of sulphonamides 11 and 12.
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assay.8,10 The N-acetylated analogues of these compounds were
prepared as previously described to give compounds 47–53
(Fig. 3).13
Using LC-MS/MS, multiple reaction monitoring of charac-
teristic transitions for the N-acetylated and corresponding
amine form of each compound was used to directly measure
the rate of conversion of the N-acetylated compound to the
free amine (Table 1). As no suitable transition was identified
for the amine form of 13, the enzymatic turnover was accessed
by reacting any free amine formed with d6-Ac2O, and measur-
ing the formation of the d3-N-acetylated form by LC-MS/MS.
Over the range of enzyme concentration that gave a linear
turnover for α-D-GlcpNAc-PI (1) the substrate analogue
α-D-GlcpNAc-IPC18 (3) was de-N-acetylated at 450% the rate of
α-D-GlcpNAc-PI (1). The increased turnover is most likely due
to improved accessibility of the compound, conferred by the
single alkyl chain, to the membranes that contain the de-
N-acetylase enzyme in the cell-free system. Of the synthetic
pseudodisaccharides (47–50) tested, only the α-anomer of the
dipalmitoylated compound 49 showed any appreciable turn-
over at 22% the rate of α-D-GlcpNAc-PI (1).
Inhibitors
Since the majority of the compounds were not processed by
the T. brucei GlcNAc-PI de-N-acetylase, we tested their ability to
inhibit the turnover of the α-D-GlcpNAc-IPC18 (3) substrate by
the T. brucei GlcNAc-PI de-N-acetylase in the LC-MS/MS assay.
Most compounds showed no inhibitory activity at 100 μM.
However, compounds 47 and 48 showed significant inhibition,
with IC50 values of 11 ± 4 μM and 37 ± 20 μM, respectively,
Fig. 3 N-Acetylated analogues.
Scheme 4 Synthesis of racemic 13.
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indicating that they can be recognised but not processed by
the T. brucei GlcNAc-PI de-N-acetylase. Interestingly, the
potency of 47 and 48 is comparable to that observed with the,
hydroxamic acid pseudodisaccharide analogue 54 (Fig. 4),
where the N-acetyl group is replaced with the zinc-chelating
hydroxamic acid (IC50 = 19 ± 0.5 μM)8 and suggests that the
zinc-chelating group may not be driving the potency of the
latter compound.
The ability of 49 and 48 to act as a substrate and inhibitor,
respectively, of the T. brucei GPI pathway was confirmed using
the trypanosome cell-free system with [3H]-mannose labelling
(Fig. 5). Priming the cell-free system with 49 produced three
bands corresponding to the addition of 1–3 mannose residues
(Fig. 5A), and, consistent with this assignment, the bands were
sensitive to jackbean α-mannosidase. As these mannosylated
compounds lack the inositol 2-OH group they cannot undergo
inositol acylation, a prerequisite for the transfer of ethanol-
amine, and thus are not processed past the Man3-species.
25
Priming the cell-free system with 3 (α-D-GlcpNAc-IPC18 at
10 μM) was eﬃciently prevented by incubation with 48 at
100 μM (Fig. 5B), confirming that inhibition of the GlcNAc-PI
de-N-acetylase is suﬃcient to prevent the formation of down-
stream GPI precursors.
Previous studies (see the introduction for more detail) have
shown that both α-D-GlcpNAc-PI (1) and β-D-GlcpNAc-PI (6) are
recognised and processed by the T. brucei GlcNAc-PI de-N-
acetylase, leading to the hypothesis that one or more of the
inositol 2, 3, 4, and 5-OH groups is/are not required. Our data
supports this hypothesis with an important caveat; when these
hydroxyl groups are removed, substrate recognition and turn-
over is dependent on both the stereochemistry of the glyco-
sidic linkage and the lipid composition. With the
diacylglycerol lipid containing compounds 49 and 50, only the
natural α-anomer 49 is both recognised and processed,
whereas the β-anomer 50 is neither a substrate nor an inhibi-
tor. However, neither the α nor β-anomer of the octadecyl lipid
containing compounds 47 and 48 is processed, although both
appear to be recognised and act as inhibitors. These sets of
diastereoisomers diﬀer only in the identity of their lipid com-
ponent, with the more flexible diacylglycerol moiety allowing
the glycan to be recognised and processed. Thus, it appears
that the requirement for the presence of inositol 2, 3, 4, and
5-OH groups for recognition by the T. brucei GlcNAc-PI de-N-
acetylase is nuanced and may depend on the conformational
flexibility of the substrate analogue.
The inability of the sulphonamide-containing compounds,
51 and 52, to act as substrates or inhibitors confirms the
importance of the phosphate group in substrate recognition. It
Table 1 Recognition of synthetic analogues by T. brucei GlcNAc-PI de-N-acetylase
Compound m/z Transition for NH2 m/z Transition for NHAc Fragment assignment Turnover/pmol/10
6 cells equiv. Relative turnovera
1 1012 > 241 972 > 241 C6H10O8P 6.1 ± 0.9 100%
3 673 > 223 715 > 223 C6H8O7P 27.0 ± 6.0 450%
47 608 > 100 650 > 100 C6H12O ND —
48 608 > 100 650 > 100 C6H12O ND —
49 906 > 255 948 > 255 O2CC15H31 1.3 ± 0.3 22%
50 906 > 255 948 > 255 O2CC15H31 ND —
51 633 > 332 592 > 332 NHSO2C18H37 ND —
52 633 > 332 592 > 332 NHSO2C18H37 ND —
53b 563 > 447 C24H47O5P ND —
a Turnover relative to α-D-GlcpNAc-PI (1). bNo suitable MRM, ND – turnover not detected. The multiple reaction monitoring (MRM) transition is
shown as [parent ion m/z] > [daughter ion m/z].
Fig. 4 The hydroxamic acid derivative.
Fig. 5 The trypanosome GPI biosynthesis in the cell-free system. A. The
T. brucei cell-free system was incubated without exogenous substrate,
with 1, α-D-GlcpNAc-PI (10 μM), or with 49 (100 μM) in the presence of
GDP-[3H]Mannose to stimulate the production of radiolabelled manno-
sylated GPI intermediates. B. Inhibition of the turnover of 3,
α-D-GlcpNAc-IPC18 (10 μM), in the presence of 48 (100 μM). Glycolipid
products were extracted, separated by high-performance thin-layer
chromatography, and visualised by ﬂuorography. DPM – dolichol-phos-
phate-mannose, M1 – Man1 species, M2 – Man2 species, M3 – Man3
species, A’ – EtNPMan3 species, where the identity and migration of the
species depends on the glycolipid substrate employed.
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may be that the presence of the negatively charged phosphate
is essential for binding at the enzyme active site.
The inactivity of compound 53 is diﬃcult to interpret. It
may be that removal of the inositol 2, 3, 4, and 5-OH groups is
not compatible with having a modified glucosamine moiety, or
that the entire glucosamine ring is required. Having said this,
the glucosamine “replacement” in compound 53 is likely to
have a considerable degree of conformational flexibility, which
could allow it to take up multiple orientations within the
active site.
Conclusions
In summary, we have prepared a series of compounds to probe
the substrate specificity and inhibition of enzymes involved at
an early stage of GPI biosynthesis. The enzyme of interest to
us, GlcNAc-PI de-N-acetylase, proved to be fastidious in its
processing of variants of α-D-GlcpN-PI. We conclude that the
glucosamine and the phospholipid moieties are essential for
binding and that, while the D-myo-inositol residue is the pre-
ferred aglycone for recognition by the enzyme, the dispensing
of it entirely with a cyclohexanediol group is tolerated but
should be used with caution. Further work on this enzyme
should focus on using the emerging structure activity relation-
ship data to develop less synthetically complex, cell permeable
analogues, which will be valuable chemical tools and may
serve as leads for a drug discovery programme.
Experimental
Synthesis general methods
1H, 13C, 31P NMR spectra were recorded on a Bruker AVANCE
500 MHz spectrometer using tetramethylsilane or the residual
solvent as the internal standard. High resolution electrospray
ionisation mass spectra [HRMS (ESI)] were recorded with a
Bruker microTof spectrometer. Melting points were deter-
mined on a Reichert hot-plate apparatus and are uncorrected.
Optical rotations were measured with a Perkin-Elmer 343
polarimeter. Thin layer chromatography (TLC) was performed
on Kieselgel 60 F254 (Merck) plates with various solvent
systems as developers, followed by detection under UV light or
by charring with sulfuric acid–water–ethanol (15 : 85 : 5).
Column chromatography was performed on Kieselgel 60
(0.040–0.063 mm) (Merck). Radial-band chromatography (RBC)
was performed using a Chromatotron (model 7924 T, TC
Research UK) with silica gel F254 TLC standard grade as the
adsorbent. Iatrobeads (6RS-8060) were purchased from SES
Analysesysteme. All reactions were carried out under argon in
commercially available dry solvents, unless otherwise stated.
1R,2R-1-O-(2-Azido-3,4,6-tri-O-acetyl-2-deoxy-
α-D-glucopyranosyl)-cyclohexanediol 16 and the β-anomer 17
After drying overnight over P2O5 in a vacuum desiccator, the
glycosyl donor14 14 (731 mg, 1.54 mmol) and the acceptor 15
(Sigma-Aldrich) were dissolved in 1 : 1 Et2O–CH2Cl2 (10 mL).
To this solution was added activated 4 Å molecular sieves (1 g)
and TMSOTf (5.4 μL, 0.03 mmol) at rt under argon. The reac-
tion mixture was stirred at rt overnight, whereafter it was neu-
tralised with TEA, percolated through a short column of silica
gel (further elution with EtOAc) and the subsequent eluent
was concentrated under reduced pressure. RBC [elution first
with PE (40–60°) and then with 3 : 2 PE (40–60°)–EtOAc] of the
residue gave first the α-linked pseudodisaccharide 16 (255 mg,
39%) as a waxy solid; [α]25D +83.7° (c 2.37, CHCl3); δH (500 MHz,
CDCl3) 5.42 (dd, 1H, J2′,3′ = J3′,4′ = 10.3 Hz, H-3′), 5.09 (d, 1H,
J1′,2′ = 3.7 Hz, H-1′), 4.95 (dd, 1H, J3′,4′ = J4′,5′ = 10.3 Hz, H-4′),
4.18 (dd, 1H, J5′,6′a = 4.8, J6′a,6′b = 12.2 Hz, H-6′a), 4.08 (m, 1H,
H-5′), 4.01 (dd, 1H, J5′,6′b = 2.2, J6′a,6′b = 12.2 Hz, H-6′b), 3.58
(dd, 1H, H-2′), 3.44 (m, 1H, H-2), 3.23 (m, 1H, H-1), 3.05 (s,
1H, 2-OH), 2.50–1.90 (m, 11H, 3 × CH3, H-3a and 6a), 1.64 (m,
2H, H-4a and 5a), 1.35–1.15 (m, 4H, H-3b, 4b, 5b and 6b); δC
(125 MHz, CDCl3) 170.6–169.8 (3 × COCH3), 99.3 (C-1′), 87.5
(C-1), 74.1 (C-2), 71.7 (C-3′), 68.6 (C-4′), 67.8 (C-5′), 62.1 (C-2′),
61.9 (C-6′), 32.0, 31.7, 24.4, 23.8, 20.7 (COCH3) 20.6 (COCH3);
HRMS (ESI) calcd for C18H27N3NaO9 [M + Na]
+ 452.1640,
found 452.1622 and then the β-anomer 17 (202 mg, 31%) as a
white solid; mp 120–122 °C; [α]25D +21.5° (c 1.15, CHCl3); δH
(500 MHz, CDCl3) 4.91 (m, 2H, H-3′ and 4′), 4.43 (d, 1H, J1′,2′ =
8.1 Hz, H-1′), 4.12 (m, 2H, H6′a and 6′b), 3.67 (m, 1H, H-5′),
3.45 (m, 1H, H-2′), 3.40–3.30 (m, 2H, H-1 and 2), 2.50–1.93 (m,
11H, 3 × CH3 and 2H-cyclitol), 1.70–1.60 (m, 2H, cyclitol) 1.35
(m, 1H, cyclitol), 1.17 (m, 3H, cyclitol); δC (125 MHz, CDCl3)
170.6–169.6 (3 × COCH3), 102.1 (C-1′), 88.2, 73.2, 72.1, 71.8
(C-5′), 68.3, 63.7 (C-2′), 61.8 (C-6′), 32.2, 30.9, 24.2, 23.6, 20.7
(COCH3), 20.6 (COCH3); HRMS (ESI) calcd for C18H28N3O9
[M + H]+ 430.1820, found 430.1831.
Triethylammonium 1R,2R-1-O-(2-azido-3,4,6-tri-O-acetyl-2-deoxy-
α-D-glucopyranosyl)-cyclohexanediol 2-(n-octadecylphosphate) 19
Each of the compounds 16 (117 mg, 0.27 mmol) and 1815
(237 mg, 0.54 mmol) were dried overnight over P2O5 in a
vacuum desiccator, whereafter anhyd pyridine was evaporated
therefrom. They were then dissolved in dry pyridine (10 mL),
pivaloyl chloride (216 μL, 1.76 mmol) was added and the
resulting solution was stirred under argon at rt for 1 h. A
freshly prepared solution of iodine (274 mg, 1.08 mmol) in
9 : 1 pyridine–water was then added and stirring of the reaction
mixture was continued for 45 min. After the addition of
CH2Cl2 (20 mL), the organic solution was washed successively
with 5% aq. NaHSO3 (25 mL), water (25 mL), 1 M TEAB buﬀer
solution (3 × 15 mL), dried (MgSO4) and concentrated under
reduced pressure. RBC of the residue (elution first with CH2Cl2
and then with 9 : 1 CH2Cl2–MeOH) aﬀorded the TEA phos-
phate derivative 19 (140 mg, 60%); [α]25D +68.6° (c 1.07, CHCl3);
δH (500 MHz, CDCl3) 5.40 (dd, 1H, J3′,4′ = 9.2 Hz, H-3′), 5.27 (d,
1H, J1′,2′ = 3.7 Hz, H-1′), 4.94 (t, 1H, J4′,5′ = 9.6 Hz, H-4′),
4.24–4.13 (m, 2H, H6′a and H-1 or 2), 4.07–3.98 (m, 2H, H-5′
and 6′b), 3.84–3.76 (m, 3H, OCH2 and H-1 or 2), 3.17 (dd, 1H,
J2′,3′ = 10.6 Hz, H-2′), 2.83 (q, 6H, J = 6.8 Hz, 3 × CH2CH3),
2.05–1.95 (m, 10H, 3 × COCH3 and 1H-cyclitol), 1.87 (m, 1H,
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cyclitol), 1.62–1.45 (m, 6H, OCH2CH2 and 4H-cyclitol),
1.33–1.14 (41H, [CH2]15, 3 × CH2CH3 and 2H-cyclitol), 0.81 (t,
3H, J = 6.8 Hz, CH2CH3); δC (125 MHz, CDCl3) 169.5–168.7 (3 ×
COCH3), 96.9 (C-1′), 76.4 (C-1 or C-2), 73.9 (C-1 or C-2), 69.4
(C-3′), 67.9 (C-4′), 66.7 (C-5′), 65.2 (OCH2), 61.1 (C-6′), 60.0
(C-2′), 44.4 [N(CH2CH3)3], 30.9, 29.7, 28.7–28.1, 24.8, 21.7,
21.0, 20.3, 19.6, 13.1 (CH2CH3), 7.5 [N(CH2CH3)3]; δP
(202 MHz, CDCl3) −0.05 (with heteronuclear decoupling);
HRMS (ESI) calcd for C36H63N3O12P [M − NEt3 − H]− 760.4155,
found 760.4154.
Triethylammonium 1R,2R-1-O-(2-azido-2-deoxy-
α-D-glucopyranosyl)-cyclohexanediol 2-(n-octadecylphosphate) 20
To a solution of compound 19 (78 mg, 0.09 mmol) in 1 : 1
CH2Cl2–MeOH (10 mL) was added 5.4 M NaOMe in MeOH
(0.10 mL). The mixture was kept for 3 h at rt and was then neu-
tralised with Amberlite IR-120 (H+) ion-exchange resin, filtered
and the filtrate concentrated under reduced pressure. Column
chromatography (elution first with 3 : 1 CH2Cl2–MeOH and
then with 2 : 1 → 1 : 1) of the residue furnished the TEA salt 20
(45 mg, 67%) as a waxy solid; [α]25D +51.6° (c 4.5, 1 : 1 THF–
MeOH); δH (500 MHz, 1 : 1 CDCl3–MeOH-d4) 5.18 (d, 1H, J1′,2′ =
3.5 Hz, H-1′), 4.25 (m, 1H, H-1 or 2), 3.96–3.65 (7H, OCH2,
H-3′, 5′, 6′a,b and H-1 or 2) 3.40 (t, 1H, J3′,4′ = J4′,5′ = 9.6 Hz,
H-4′), 3.13 (q, 6H, J = 7.3 Hz, 3 × CH2CH3), 3.06 (dd, 1H, J2′,3′ =
10.5 Hz, H-2′), 2.03 (m, 1H, cyclitol), 1.90 (m, 1H, cyclitol),
1.64 (m, 6H, OCH2CH2 and 4H-cyclitol), 1.43–1.22 (41H,
[CH2]15, 3 × CH2CH3 and 2H-cyclitol), 0.88 (t, 3H, J = 6.8 Hz,
CH2CH3); δC (125 MHz, 1 : 1 CDCl3–MeOH-d4) 98.7 (C-1′), 76.3
(C-1 or C-2), 74.2 (C-1 or C-2), 73.8 72.4, 72.3, 66.9 (OCH2), 64.5
(C-2′), 62.7, 47.4 [N(CH2CH3)3], 32.0, 31.0–30.6, 29.8, 29.5,
27.1, 23.9, 22.5, 22.1, 15.0 (CH2CH3), 9.6 [N(CH2CH3)3]; δP
(202 MHz, 1 : 1 CDCl3–MeOH-d4) −0.47 (with heteronuclear
decoupling); HRMS (ESI) calcd for C30H57N3O9P [M − NEt3 −
H]− 634.3838, found 634.3850.
1R,2R-1-O-[2-(4-Hydroxybutyl)amino-2-deoxy-
α-D-glucopyranosyl]-cyclohexanediol 2-(n-octadecylphosphate) 21
A solution of the azido compound 20 (45 mg, 0.06 mmol) in
1 : 1 THF–MeOH (5 mL) containing 10–20% Pd(OH)2 on
carbon (15 mg) was stirred under a hydrogen atmosphere at rt
for 30 min before it was percolated through a short column of
Chelex 100 on a bed of Celite (further elution with 1 : 1 THF–
MeOH). The eluent was concentrated under reduced pressure
and the ensuing residue was purified by column chromato-
graphy (elution gradient 6 : 1→ 4 : 1 CH2Cl2–MeOH) to give the
hydroxybutylamino compound 21 (15 mg, 38%); [α]25D +34.0° (c
1.5, 1 : 1 CHCl3–MeOH); δH (500 MHz, 1 : 1 CDCl3–MeOH-d4)
5.43 (d, 1H, J1′,2′ = 3.6 Hz, H-1′), 4.05 (m, 1H, H-1 or 2), 3.93
(dd, 1H, J3′,4′ = 10.4 Hz, H-3′), 3.90–3.50 (8H, OCH2 butyl,
POCH2, H-5′, 6′a,b and H-1 or 2), 3.38 (m, 1H, H-4′), 3.17 (t,
2H, J = 7.6 Hz, NCH2), 3.00 (dd, 1H, J2′,3′ = 10.4 Hz, H-2′), 2.18
(m, 1H, cyclitol), 2.08 (m, 1H, cyclitol), 1.86 (m, 2H, CH2
butyl), 1.76–1.57 (6H, POCH2CH2, CH2 butyl and 2H-cyclitol),
1.45–1.20 (34H, [CH2]15 and 4H-cyclitol), 0.89 (t, 3H, J = 6.8 Hz,
CH2CH3); δC (125 MHz, 1 : 1 CDCl3–MeOH-d4) 97.3 (C-1′), 83.2
(C-1 or C-2), 79.3 (C-1 or C-2), 74.0, 71.8, 71.7, 67.1, 62.3, 61.6
(C-2′), 54.8, 50.6, 48.7 (NCH2), 34.2, 33.6, 31.9, 30.9–30.6, 27.0,
25.3, 25.2, 15.0 (CH2CH3); δP (202 MHz, 1 : 1 CDCl3–MeOH-d4)
0.66 (with heteronuclear decoupling); HRMS (ESI) calcd for
C34H67NO10P [M − H]− 680.4508, found 680.4554.
1R,2R-1-O-(2-Amino-2-deoxy-α-D-glucopyranosyl)-
cyclohexanediol 2-(n-octadecylphosphate) 7
A solution of the TEA salt 20 (52 mg, 0.07 mmol) in 1 : 1 stabil-
ised THF–MeOH (5 mL) containing 10–20% Pd(OH)2 on
carbon (5 mg) was stirred under a hydrogen atmosphere at rt
for 1 h. Work-up as described for the derivative 21 gave, after
column chromatography (5 : 1 CH2Cl2–MeOH), the amino com-
pound 7 (33 mg, 77%); [α]25D +57.5° (c 3.3, 1 : 1 CHCl3–MeOH);
δH (500 MHz, 1 : 1 CDCl3–MeOH-d4), 5.42 (d, 1H, J1′,2′ = 3.9 Hz,
H-1′), 4.05 (m, 1H, H-1 or 2), 3.90–3.65 (6H, OCH2, H-3′, 5′, 6′a,
b), 3.58 (m, 1H, H-1 or 2) 3.32 (m, 3H, H-4′ and MeOH-d4),
3.05 (dd, 1H, J2′,3′ = 10.5 Hz, H-2′), 2.10 (m, 2H, 2H-cyclitol),
1.74–1.57 (4H, OCH2CH2 and 2H-cyclitol), 1.44–1.21 (34H,
[CH2]15 and 4H-cyclitol), 0.90 (t, 3H, J = 6.8 Hz, CH2CH3); δC
(125 MHz, 1 : 1 CDCl3–MeOH-d4) 97.9 (C-1′), 81.8 (C-1 or C-2),
79.9 (C-1 or C-2), 74.5, 71.8, 71.7, 66.7 (OCH2), 62.4 (C-6′), 55.8
(C-2′), 34.0, 33.4, 33.1, 31.9, 31.8, 30.8, 30.5, 26.9, 25.2, 25.1,
23.8, 14.5 (CH2CH3); δP (202 MHz, 1 : 1 CDCl3–MeOH-d4) 0.54
(with heteronuclear decoupling); HRMS (ESI) calcd for
C30H61NO9P [M + H]
+ 610.4078, found 610.4050.
1R,2R-1-O-(2-Azido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl)-
2-O-(tert-butyldimethylsilyl)-cyclohexanediol 22
The alcohol 16 (284 mg, 0.66 mmol) was dried overnight in a
desiccator over P2O5 under high vacuum and then dissolved in
anhyd. CH2Cl2 (10 mL). To this solution, at room temperature,
was added 2,6-lutidine (154 μL, 1.32 mmol) and tert-butyldi-
methylsilyl trifluoromethane sulfonate (228 μL, 0.99 mmol).
After 30 min, CH2Cl2 (25 mL) and brine (25 mL) were added
and the organic layer separated. The aqueous layer was re-
extracted with CH2Cl2 (25 mL) and the combined organic
layers were washed with brine (2 × 25 mL), dried (MgSO4) and
concentrated under reduced pressure. RBC [elution first with
PE (40–60°) and then with 1 : 1 PE(40–60°)–Et2O] of the residue
gave the azide 22 (284 mg, 79%) as an oil; [α]25D +90.2° (c 1.52,
CHCl3); δH (500 MHz, CDCl3) 5.40 (t, 1H, J2′,3′ = J3′,4′ = 9.7 Hz,
H-3′), 5.35 (d, 1H, J1′,2′ = 3.3 Hz, H-1′), 5.20 (t, 1H, J3′,4′ = J4′,5′ =
9.7 Hz, H-4′), 4.26 (dd, 1H, J5′,6′a = 4.7, J6′a,6′b = 12.1 Hz, H-6′a),
4.10 (m, 2H, H-5′ and 6′b), 3.75 (m, 1H, H-1 or 2), 3.57 (m, 1H,
H-1 or 2), 3.17 (dd, 1H, H-2′), 2.10–2.03 (3 × s, 9H, 3 × COCH3),
1.89 (m, 2H-cyclitol), 1.70–1.25 (6H-cyclitol), 0.89 (s, 9H, 3 ×
CH3), 0.12–0.08 (2 × s, 6H, 2 × CH3); δC (125 MHz, CDCl3)
170.6–169.7 (3 × COCH3), 97.9 (C-1′), 79.7 (C-1 or 2), 72.6 (C-1
or 2), 70.4 (C-3′), 68.7 (C-4′), 67.6 (C-5′), 62.1 (C-6′), 61.0 (C-2′),
32.5, 29.8, 25.9, 22.1, 20.7 (COCH3), 20.6 (COCH3), 18.0, −4.1,
−4.9; HRMS (ESI) calcd for C24H42N3O9Si [M + H]+ 544.2685,
found 544.2698.
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1R,2R-1-O-(2-Azido-2-deoxy-α-D-glucopyranosyl)-2-O-(tert-
butyldimethylsilyl)-cyclohexanediol 23
To a solution of the triacetate 22 (185 mg, 0.34 mmol) in 1 : 1
CH2Cl2–MeOH (92 mL) was added 5.4 M NaOMe in MeOH
(230 μL). The mixture was kept for 30 min at rt and was then
neutralised with Amberlite IR-120 (H+) ion-exchange resin, fil-
tered and the filtrate concentrated under reduced pressure.
The residue, so obtained, was percolated through a short
silica-gel column (further elution with EtOAc) and the eluent
was concentrated under reduced pressure to aﬀord the triol 23
(136 mg, 96%) as a white solid, mp 122–123 °C (from
10 : 1 hexane–Et2O); [α]
25
D +84.1° (c 1.63, CHCl3); δH (500 MHz,
CDCl3) 5.22 (d, 1H, J1′,2′ = 3.4 Hz, H-1′), 4.02 (t, 1H, J3′,4′ =
9.4 Hz, H-3′), 3.90 (dd, 1H, J5′,6′a = 2.3, J6′a,6′b = 11.6 Hz, H-6′a),
3.81 (dd, 1H, J5′,6′b = 2.2, J6′a,6′b = 11.6 Hz, H-6′b), 3.73 (m, 2H,
H-5′ and H-1 or 2), 3.65 (t, 1H, J4′,5′ = 9.4 Hz, H-4′), 3.59 (m, 1H,
H-1 or 2), 3.15 (dd, 1H, J2′,3′ = 10.4 Hz H-2′), 1.85 (m, 2H, cycli-
tol), 1.60 (m, 2H, cyclitol) 1.50–1.20 (4H, cyclitol), 0.89 (s, 9H,
3 × CH3), 0.12–0.08 (2 × s, 6H, 2 × CH3); δC (125 MHz, CDCl3)
98.2 (C-1′), 78.9 (C-1 or 2), 71.5, 71.4, 70.5 (C-4′), 62.9 (C-2′),
61.6 (C-6′), 31.9, 29.4, 25.9, 22.5, 21.7, 18.0, −4.3, −4.9; HRMS
(ESI) calcd for C18H36N3O6Si [M + H]
+ 418.2368, found
418.2365.
1R,2R-1-O-(2-Azido-3,4,6-tri-O-benzyl-2-deoxy-α-D-glucopyranosyl)-
2-O-(tert-butyldimethylsilyl)-cyclohexanediol 24
To a stirred and cooled (0 °C) solution of the triol 23 (70 mg,
0.17 mmol) in DMF (10 mL) under argon was added NaH
(19 mg, 0.78 mmol) and the solution was stirred for 15 min
before benzyl bromide (93 μL, 0.78 mmol) was added drop-
wise. The reaction mixture was stirred at rt overnight and then
poured slowly and carefully into ice-cold water (50 mL). After
dilution with EtOAc (50 mL), the EtOAc solution was washed
with brine (25 mL), dried (Na2SO4) and concentrated under
reduced pressure. RBC [elution gradient PE (40–60°) → 10 : 1
→ 7 : 1 → 4 : 1 PE (40–60°)–Et2O] of the residue yielded the
fully protected compound 24 (86 mg, 74%); [α]25D +57.9° (c 1.78,
CHCl3); δH (500 MHz, CDCl3) 7.33–7.03 (15H, 3 × Ph), 5.17 (d,
1H, J1′,2′ = 3.6 Hz, H-1′), 4.84–4.37 (6H, 3 × CH2Ar), 3.93 (t, 1H,
J3′,4′ = 9.0 Hz, H-3′), 3.83 (m, 1H, H-5′), 3.72–3.60 (m, 3H, H-4′,
6′a and 1 or 2), 3.57 (dd, 1H, J5′,6′b = 2.0, J6′a,6′b = 10.7 Hz, H-6′
b), 3.48 (m, 1H, H-1 or 2), 3.26 (dd, 1H, J2′,3′ = 10.3 Hz, H-2′),
1.80 (m, 2H, cyclitol), 1.32 (m, 2H, cyclitol), 1.40–1.10 (4H,
cyclitol), 0.82 (s, 9H, 3 × CH3), 0.02–0.00 (2 × s, 6H, 2 × CH3);
δC (125 MHz, CDCl3) 137.0–136.8 (Ph), 127.4–126.7 (Ph), 97.0
(C-1′), 79.2 (C-3′), 77.9 (C-1 or 2), 77.4, 74.3, 74.1, 72.5, 71.3,
69.8 (C-5′), 67.3 (C-6′), 62.6 (C-2′), 31.3, 28.7, 24.5, 21.7, 21.0,
18.4, −5.2, −5.8; HRMS (ESI) calcd for C39H54N3O6Si [M + H]+
688.3776, found 688.3780.
1R,2R-1-O-(2-Amino-3,4,6-tri-O-benzyl-2-deoxy-α-D-glucopyranosyl)-
2-O-(tert-butyldimethylsilyl)-cyclohexanediol 25
To a stirred solution of 24 (86 mg, 0.12 mmol) in 10 : 1 THF–
water (5 mL) at 60 °C was added Ph3P (98 mg, 0.38 mmol).
After 3 h, TLC showed the complete disappearance of the
starting material. The reaction was then cooled to rt, poured
into water (25 mL) and extracted with CH2Cl2 (3 × 25 mL). The
combined organics were washed successively with water
(25 mL), brine (25 mL), dried (MgSO4) and concentrated under
reduced pressure. RBC [elution gradient hexane → 7 : 1 → 3 : 1
→ 1 : 1 → 1 : 3 hexane–EtOAc] of the residue aﬀorded the
amino derivative 25 (53 mg, 62%); [α]25D +65.6° (c 1.09, CHCl3);
δH (500 MHz, CDCl3) 7.35–7.09 (15H, 3 × Ph), 4.98–4.44 (7H,
H-1′ and 3 × CH2Ar), 3.87 (m, 1H, H-5′), 3.75 (dd, 1H, J5′,6′a =
3.6, J6′a,6′b = 10.6 Hz, H-6′a), 3.61 (m, 3H, H-4′, 6′b and 1 or 2),
3.55 (t, 1H, J3′,4′ = 9.2 Hz, H-3′), 3.45 (m, 1H, H-1 or 2), 2.77 (dd,
1H, J1′,2′ = 3.7, J2′,3′ = 9.7 Hz, H-2′), 1.98 (m, 1H, cyclitol), 1.70
(m, 1H, cyclitol), 1.63–1.16 (6H, cyclitol), 0.84 (s, 9H, 3 × CH3),
0.00 (2 × s, 6H, 2 × CH3); δC (125 MHz, CDCl3) 138.7–138.0 (Ph),
128.5–127.7 (Ph), 100.2 (C-1′), 84.1 (C-3′), 79.9 (C-1 or 2), 78.9,
75.6, 74.9, 73.5, 71.4 (C-5′), 71.0, 68.7 (C-6′), 56.4 (C-2′), 31.9,
29.4, 25.9, 22.4, 21.8, 18.0, −4.3, −4.4; HRMS (ESI) calcd for
C39H56NO6Si [M + H]
+ 662.3871, found 662.3874.
1R,2R-1-O-[2-N-(tert-Butoxycarbonyl)amino-3,4,6-tri-O-benzyl-
2-deoxy-α-D-glucopyranosyl]-2-O-(tert-butyldimethylsilyl)-
cyclohexanediol 26
The amine 25 (147 mg, 0.22 mmol) was dissolved in EtOAc
(10 mL) at rt. Di-tert-butyldicarbonate (58 mg, 0.26 mmol) was
then added and the mixture was stirred overnight at rt. After-
wards, the reaction mixture was diluted with EtOAc (25 mL)
and then washed successively with water (25 mL), brine
(25 mL), dried (Na2SO4) and concentrated under reduced
pressure. RBC [elution gradient hexane → 7 : 1 → 5 : 1 hexane–
EtOAc] of the residue aﬀorded the Boc protected derivative 26
(132 mg, 79%); [α]25D +39.0° (c 1.06, CHCl3); δH (500 MHz,
CDCl3) 7.30–7.05 (15H, 3 × Ph), 4.95 (d, 1H, J1′,2′ = 3.3 Hz,
H-1′), 4.76–4.38 (7H, NH and 3 × CH2Ar), 3.90 (m, 1H, H-2′)
3.83 (m, 1H, H-5′), 3.69 (dd, 1H, J5′,6′a = 4.1, J6′a,6′b = 10.7 Hz,
H-6′a), 3.61 (m, 3H, H-3′, 4′, and 6′b), 3.48 (m, 1H, H-1 or 2),
3.37 (m, 1H, H-1 or 2), 2.01 (m, 1H, cyclitol), 1.74 (m, 1H, cycli-
tol), 1.52 (m, 2H, cyclitol), 1.35 (s, 9H, 3 × BocCH3), 1.30–1.10
(4H, cyclitol), 0.83 (s, 9H, 3 × CH3), 0.00 (2 × s, 6H, 2 × CH3); δC
(125 MHz, CDCl3) 155.3 (CvO), 138.6–138.2 (Ph), 128.4–127.5
(Ph), 99.1 (C-1′), 81.5, 81.3 (C-1 or 2), 79.5, 78.5, 75.3, 75.1,
73.4, 73.2 (C-1 or 2), 71.4 (C-5′), 68.8 (C-6′), 54.6 (C-2′), 33.4,
30.8, 28.5, 26.1, 23.3, 22.9, 18.1, −3.9, −4.3; HRMS (ESI) calcd
for C44H64NO8Si [M + H]
+ 762.4396, found 762.4393.
1R,2R-1-O-[2-N-(tert-Butoxycarbonyl)amino-3,4,6-tri-O-benzyl-
2-deoxy-α-D-glucopyranosyl]-cyclohexanediol 27
To a stirred solution of the silyl derivative 26 (114 mg,
0.15 mmol) in THF (10 mL) at 0 °C was added ∼70% HF-pyri-
dine (90 μL). The solution was stirred overnight at rt whereafter
a further aliquot of ∼70% HF-pyridine (90 μL) was added and
the solution was left to stir overnight; this process was contin-
ued on day 3. On day 4, TLC revealed the complete disappear-
ance of the starting material, whereafter satd NaHCO3 (1 mL)
was added dropwise to quench the reaction and the resulting
solution was poured into brine (25 mL) and extracted with
EtOAc (3 × 25 mL). The EtOAc extracts were combined and
Organic & Biomolecular Chemistry Paper
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washed with brine (25 mL), dried (MgSO4) and concentrated
under reduced pressure. RBC [elution gradient hexane →
2 : 1 hexane–EtOAc] of the residue furnished the alcohol 27
(97 mg, 49%); [α]25D +27.2° (c 1.08, CHCl3); δH (500 MHz,
CDCl3) 7.36–7.10 (15H, 3 × Ph), 5.12 (d, 1H, J1′,2′ = 3.6 Hz,
H-1′), 4.86–4.44 (7H, NH and 3 × CH2Ar), 3.95 (dd, 1H, J3′,4′ =
J4′,5′ = 9.7 Hz, H-4′), 3.86 (m, 1H, H-2′), 3.75–3.61 (4H, H-3′, 5′
and 6′a,b), 3.47 (m, 1H, H-1 or 2), 3.32 (m, 1H, H-1 or 2),
2.10–1.91 (2H, cyclitol), 1.65 (m, 2H, cyclitol), 1.43 (s, 9H,
3 × CH3), 1.33–1.16 (4H, cyclitol); δC (125 MHz, CDCl3)
155.6 (CvO), 138.4–138.0 (Ph), 128.4–127.7 (Ph), 99.5
(C-1′), 85.0 (C-1 or 2), 80.5, 79.7, 78.5, 75.0, 74.0 (C-1 or 2),
73.4, 71.2 (C-4′), 68.7 (C-6′), 54.9 (C-2′), 32.9, 31.7, 28.4, 24.3,
23.9; HRMS (ESI) calcd for C38H50NO8 [M + H]
+ 648.3531,
found 648.3527.
Triethylammonium 1R,2R-1-O-[2-N-(tert-butoxycarbonyl)-
amino-3,4,6-tri-O-benzyl-2-deoxy-α-D-glucopyranosyl]-
cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol
3-phosphate) 29
This compound was obtained from the alcohol 27 (55.7 mg,
0.086 mmol) and 1,2-di-O-hexadecanoyl-sn-glycerol 3-hydrogen-
phosphonate TEA salt 2819 (126 mg, 0.17 mmol) in the pres-
ence of pivaloyl chloride (69 μL, 0.56 mmol) essentially as
described for the 2-(n-octadecyl phosphate) 19. After the oxi-
dation with iodine (87 mg, 0.34 mmol) in 9 : 1 pyridine–water
followed by the same aqueous workup as described for 19,
RBC (elution first with CH2Cl2 and then with 20 : 1 → 15 : 1
CH2Cl2–MeOH) aﬀorded the TEA phosphate derivative 29
(57 mg, 52%) as an opaque oil; [α]25D +27.7° (c 1.08, CHCl3); δH
(500 MHz, CDCl3) 12.5 (brs, 1H, NH TEA salt), 7.36–7.10 (15H,
3 × Ph), 5.24 (m, 1H, H-2 glycerol), 4.96 (s, 1H, H-1′), 4.84–4.44
(6H, 3 × CH2Ar), 4.39 (m, 1H, 1- or 3-CHa glycerol), 4.17 (dd,
1H, J = 6.6, J = 12.0 Hz, 1- or 3-CHb glycerol), 4.13–3.97 (m, 4H,
H-2′, 1 or 2 cyclitol and 1- or 3-CH2 glycerol), 3.95 (m, 1H,
H-4′), 3.85 (t, J2′,3′ = J3′,4′ = 9.9 Hz, H-3′), 3.74 (dd, 1H, J5′,6′a =
4.1, J6′a,6′b = 10.7 Hz, H-6′a), 3.66 (m, 2H, H-5′ and 6′b), 3.50
(m, 1H, H-1 or 2), 2.97 (q, 6H, J = 7.1 Hz, 3 × CH2CH3), 2.27
(m, 4H, 2 × COCH2), 2.21–1.95 (2H, cyclitol), 1.72–1.50 (m, 6H,
2 × COCH2CH2 and 2H cyclitol), 1.44 (s, 9H, 3 × CH3),
1.33–1.18 (61H, 3 × CH2CH3, 2 × [CH2]12 and 4H cyclitol), 0.88
(t, 6H, J = 7.3 Hz, 2 × CH2CH3); δC (125 MHz, CDCl3) 172.4
(CvO), 171.9 (CvO), 155.4 (CvO), 138.9–137.4 (Ph),
127.3–126.3 (Ph), 98.9 (C-1′), 80.0, 76.8, 73.7, 72.7, 72.3, 70.3,
69.8, 69.5, 68.1, 67.6, 62.4, 61.8, 61.4, 53.5, 44.2 [N(CH2CH3)3],
33.3, 33.1, 30.9, 30.2, 28.7–28.1, 27.5, 23.4, 21.7, 13.1, 7.40
[N(CH2CH3)3]; δP (202 MHz, CDCl3) 0.04 (with heteronuclear
decoupling); HRMS (ESI) calcd for C73H115NO15P [M − NEt3 −
H]− 1276.8010, found 1276.8015.
1R,2R-1-O-[2-N-(tert-Butoxycarbonyl)amino-2-deoxy-α-D-
glucopyranosyl]-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-
glycerol 3-phosphate) 30
A solution of the benzylated compound 29 (57 mg,
0.041 mmol) in 1 : 1 THF–n-propanol (10 mL) containing
10–20% Pd(OH)2 on carbon (15 mg) was stirred under 3 atm of
hydrogen for 3 h before it was percolated through a short
column of Chelex 100 on a bed of Celite (further elution with
1 : 1 THF–n-propanol). The eluent was concentrated under
reduced pressure and the ensuing residue was purified by
column chromatography (elution gradient 7 : 1 → 4 : 1 CH2Cl2–
MeOH) to give the Boc protected derivative 30 (30 mg, 73%);
[α]25D +39.1° (c 3.00, 1 : 1 CH2Cl2–MeOH); δH (500 MHz, 1 : 1
CDCl3–MeOH-d4) 5.25 (m, 1H, H-2 glycerol), 4.90 (s, 1H, H-1′),
4.45 (m, 1H, 1- or 3-CHa glycerol), 4.20 (dd, 1H, J = 6.7, J = 11.7
Hz, 1- or 3-CHb glycerol), 4.00 (m, 2H, 1- or 3-CH2 glycerol), 3.75
(m, 1H, H-3′ and 4′), 3.65 (m, 1H, H-1 or 2), 3.55 (dd, 1H, J1′,2′ =
3.0, J2′,3′ = 10.5 Hz, H-2′), 3.47 (m, 1H, H-1 or 2), 3.40 (m, 3H,
H-5′ and 6′a,b), 2.40–2.00 (m, 6H, 2 × COCH2 and 2H cyclitol),
1.74–1.57 (m, 6H, 2 × COCH2CH2 and 2H cyclitol), 1.47 (s, 9H,
3 × CH3), 1.40–1.20 (52H, 2 × [CH2]12 and 4H cyclitol), 0.89 (t, 6H,
J = 7.1 Hz, 2 × CH2CH3); δC (125 MHz, 1 : 1 CDCl3–MeOH-d4) 174.6
(CvO), 174.1 (CvO), 158.2 (CvO), 98.9 (C-1′), 82.0, 78.0, 73.3,
73.0, 72.0, 71.1, 64.0, 63.1, 62.0, 57.1, 56.4, 34.7, 34.5, 33.0–29.5,
28.5, 25.4, 24.3, 23.5, 23.1, 14.3; δP (202 MHz, 1 : 1 CDCl3–MeOH-
d4) −0.28 (with heteronuclear decoupling); HRMS (ESI) calcd for
C52H97NO15P [M − H]− 1006.6601, found 1006.6635.
1R,2R-1-O-(2-Amino-2-deoxy-α-D-glucopyranosyl)-
cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol
3-phosphate) 9
To a solution of the tert-butoxycarbonyl protected compound
30 (30 mg, 0.030 mmol) in 1 : 1 CH2Cl2–MeOH (1 mL) was
added 9 : 1 trifluoroacetic acid (TFA)–water (5 mL). After stir-
ring 3 h at rt, toluene (5 mL) was added and the solvents were
removed under reduced pressure. Toluene (2 × 5 mL) was evap-
orated oﬀ twice from the residue (to remove traces of TFA and
water) to give the pseudodisaccharide phosphate derivative 9
(25 mg, 93%) which did not require any further purification;
[α]25D +28.0° (c 2.50, 1 : 1 CHCl3–MeOH); δH (500 MHz, 1 : 1
CDCl3–MeOH-d4) 5.28 (d, 1H, J1′,2′ = 3.7 Hz, H-1′), 5.14 (m, 1H,
H-2 glycerol), 4.34 (dd, 1H, J = 3.2, J = 12.0 Hz, 1- or 3-CHa gly-
cerol), 4.10 (dd, 1H, J = 6.6, J = 12.0 Hz, 1- or 3-CHb glycerol),
3.96 (m, 1H, H-1 or 2), 3.88 (m, 2H, 1- or 3-CH2 glycerol), 3.71
(m, 3H, H-3′ and 6′a,b), 3.62 (dd, 1H, J4′,5′ = 9.4, J5′,6′ = 3.9 Hz,
H-5′), 3.45 (m, 1H, H-1 or 2), 3.33 (t, 1H, J3′,4′ = 9.4 Hz, H-4′),
2.96 (dd, 1H, J2′,3′ = 10.5 Hz, H-2′), 2.24 (m, 4H, 2 × COCH2),
2.0 (m, 2H, cyclitol), 1.68–1.47 (m, 6H, 2 × COCH2CH2 and 2H
cyclitol), 1.35–1.14 (52H, 2 × [CH2]12 and 4H cyclitol), 0.79 (t,
6H, J = 7.1 Hz, 2 × CH2CH3); δC (125 MHz, 1 : 1 CDCl3–MeOH-
d4) 175.3 (CvO), 174.8 (CvO), 98.0 (C-1′), 82.5 (C-1 or 2), 80.2
(C-1 or 2), 74.2 (C-5′), 71.6, 71.5, 71.4, 64.8 (CH2 glycerol), 63.8
(CH2 glycerol), 62.3 (C-6′), 55.7 (C-2′), 35.5, 35.4, 34.0, 33.5,
33.2, 31.0–30.4, 26.2, 25.3, 23.9, 15.1; δP (202 MHz, 1 : 1 CDCl3–
MeOH-d4) 0.10 (with heteronuclear decoupling); HRMS (ESI)
calcd for C52H97NO15P [M − H]− 906.6077, found 906.6094.
N-[(1R,2R)-2-(Benzyloxy)cyclohexyl]octadecane-
1-sulphonamide 32
To a solution of CH2Cl2 (10 mL) and triethylamine (2.1 mL)
under argon was added (1R, 2R)-1-amino-2-benzyloxycyclo-
hexane 31 (1.0 g, 4.87 mmol) and 1-octadecanesulfonyl
Paper Organic & Biomolecular Chemistry
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chloride (2.1 g, 5.95 mmol), purchased from Sigma-Aldrich
and Alfa Aesar, respectively. The reaction mixture was stirred at
rt overnight, whereafter it was diluted with CH2Cl2 (40 mL),
washed successively with water (25 mL), brine (25 mL), dried
(MgSO4) and concentrated under reduced pressure. RBC
(elution first with hexane and then with a gradient of 5 : 1 →
3 : 1 hexane–EtOAc) gave the sulphonamide 32 (1.9 g, 76%) as
white needles; mp 63–64 °C; [α]25D −35.6° (c 1.00, CHCl3); δH
(500 MHz, CDCl3) 7.40–7.20 (m, 5H, Ph), 4.68 (d, 1H, J = 1.4
Hz, OCH2), 4.46 (d, 1H, J = 5.0 Hz, NH), 3.23–3.11 (m, 2H, H1
and 2), 3.03–2.90 (m, 2H, SO2CH2), 2.23 (m, 2H, H3a and 6a),
1.80–1.60 (m, 4H, SO2CH2CH2, H4a and 5a), 1.35–1.11 (m,
34H, 15 × [CH2]15, H3b, 4b, 5b and 6b), 0.88 (t, 3H, J = 6.8 Hz,
CH2CH3); δC (125 MHz, CDCl3) 138.1, 128.5, 127.8, 127.7, 80.1
(C1 or 2), 70.6 (OCH2), 57.6 (C1 or 2), 53.2 (SO2CH2), 33.2 (C3
or 6), 31.9, 30.1 (C3 or 6), 29.7, 29.5, 29.4, 29.1, 28.3, 24.2, 23.8,
23.5, 22.7, 14.1 (CH2CH3); HRMS (ESI) calcd for C31H56NO3S
[M + H]+ 522.3975, found 522.3981.
N-[(1R,2R)-2-Hydroxycyclohexyl]octadecane-1-sulphonamide 33
A solution of the benzyloxysulphonamide 32 (200 mg,
0.38 mmol) in 5 : 1 THF–AcOH (6 mL) containing 10–20% Pd-
(OH)2 on carbon (50 mg) was stirred under a slight over
pressure of hydrogen at room temperature for 2 h before it was
percolated through a short column of Celite on a bed of silica
gel (further elution with EtOAc). The eluent was concentrated
under reduced pressure to give the deprotected alcohol 33
(140 mg, 85%) as a white solid which was used without any
further purification; mp 101–102 °C; [α]25D −7.3 (c 3.40, CHCl3);
δH (500 MHz, CDCl3) 4.54 (d, 1H, J = 7.4 Hz, NH), 3.32 (m, 1H,
H2), 3.15–3.02 (m, 3H, SO2CH2 and H1), 2.54 (brs, 1H, OH),
2.12–2.03 (m, 2H, H3a and 6a), 1.90–1.63 (m, 4H, SO2CH2CH2,
H4a and 5a), 1.50–1.10 (m, 34H, [CH2]15, H3b, 4b, 5b and 6b),
0.88 (t, 3H, J = 6.8 Hz, CH2CH3); δC (125 MHz, CDCl3) 73.8
(C2), 59.8 (C1), 53.5 (SO2CH2), 34.1 (C3 or 6), 31.9, 29.7, 29.6,
29.5, 29.3, 29.1, 28.3, 24.8 (C4 or 5), 24.0 (C4 or 5), 23.7, 14.1
(CH2CH3); HRMS (ESI) calcd for C24H50NO3S [M + H]
+
432.3506, found 432.3487.
N-(1R,2R)-2-O-(2-Azido-3,4,6-tri-O-benzyl-2-deoxy-
D-glucopyranosyl)-cyclohexyloctadecane-1-sulphonamide 35
A mixture of trichloroacetimidate 3420 (130 mg, 0.21 mmol),
acceptor 33 (109 mg, 0.25 mmol) and activated 4 Å molecular
sieves (200 mg) in dry CH2Cl2 (15 mL) was stirred under argon
at room temperature for 15 min. Then TMSOTf (5.3 μL,
0.029 mmol) was added and the solution was stirred at room
temperature for an additional 2 h. It was then percolated
through a short column of silica gel (elution with EtOAc) and
the eluent was concentrated under reduced pressure. RBC
(elution gradient 1 : 5 → 1 : 3 EtOAc–hexane) of the residue
gave the pseudodisaccharide 35 (140 mg, 75%) as an oily
mixture of α, β anomers in the ratio of ∼1 : 1, as determined by
1H NMR spectroscopy; δH (500 MHz, CDCl3) 7.40–7.10 (30H,
6 × Ph α and β), 5.62 (d, 1H, J = 2.5 Hz, NH α or β), 5.46 (s, 1H,
NH α or β), 4.98 (d, 1H, J1′,2′ = 3.6 Hz, H1′α), 4.90–4.44 (m, 12H,
6 × CH2Ph α and β), 4.30 (d, 1H, J1′,2′ = 8.0 Hz, H1′β), 3.91 (m,
2H), 3.77–3.57 (m, 7H), 3.47 (m, 1H), 3.42–3.27 (m, 4H), 3.17
(m, 1H, H1 α/β or 2 α/β), 3.10–2.96 (m, 4H, 2 × SO2CH2), 2.37
(m, 2H, cyclitol), 2.13 (m, 2H, cyclitol), 1.90–1.18 (α and β
SO2CH2CH2, [CH2]15 and H’s cyclitol), 0.88 (t, 6H, J = 7.1 Hz, 2
× CH2CH3 α and β); δC (125 MHz, CDCl3) 137.9, 137.8, 137.6,
128.5–127.7 (Ph), 101.2 (C1′β), 99.6 (C1′α), 83.7, 82.7, 82.3,
81.4, 78.1, 77.5, 75.8, 75.6, 75.3, 75.1, 74.9, 73.6, 73.5, 71.4,
68.6, 68.2, 66.2, 64.7, 57.9 (C1 α/β or C2 α/β), 57.5, 53.6, 51.9,
34.0, 32.3, 32.0, 31.9, 31.4, 29.7, 29.5, 29.4, 29.3, 28.6, 28.5,
24.2, 23.8, 23.5, 23.4, 22.7, 14.2 (CH2CH3 α and β); HRMS (ESI)
calcd for C51H76N4O7SNa [M + Na]
+ 911.5372, found 911.5282.
N-(1R,2R)-2-O-(2-Amino-2-deoxy-β-D-glucopyranosyl)-
cyclohexyloctadecane-1-sulphonamide 11 and the α-anomer 12
A solution of the anomeric mixture 35 (108 mg, 0.12 mmol) in
5 : 1 THF–AcOH (6 mL) containing 10–20% Pd(OH)2 on carbon
(25 mg) was stirred under a slight over pressure of hydrogen at
room temperature for 24 h before it was filtered through a bed
of Celite. The catalyst was further washed with 1 : 1 THF–
MeOH (2 × 10 mL) and the washings were combined and con-
centrated under reduced pressure. Column chromatography
(9 : 1 CH2Cl2–MeOH) gave first the β anomer 11 (9.8 mg, 14%)
as a waxy solid; [α]25D +2.5 (c 0.98, MeOH); δH (500 MHz, MeOH-
d4) 4.44 (d, 1H, J1′,2′ = 8.1 Hz, H1′), 3.94 (dd, 1H, J5′,6′a = 2.1,
J6a′,6′b = 11.7 Hz, H6′a), 3.65–3.50 (m, 2H, H1 or 2 and 6′b),
3.34 (m, 2H, H3′ and 5′), 3.22 (q, 1H, J3′,4′ = J4′,5′ = 9.2 Hz, H4′),
3.09 (m, 3H, H1 or 2 and SO2CH2), 2.63 (t, 1H, J2′,3′ = 9.0 Hz,
H2′), 2.13 (m, 2H, cyclitol), 1.90–1.20 (38H, SO2CH2CH2,
[CH2]15 and 6H cyclitol), 0.89 (t, 3H, J = 7.0 Hz, CH2CH3); δC
(125 MHz, MeOH-d4) 100.7 (C1′), 80.5 (C1 or 2), 78.5 (C3′ or
5′), 72.2 (C4′), 62.9 (C6′), 58.1 (C1 or 2 or 2′), 58.0 (C1 or 2 or
2′), 54.1 (SO2CH2), 35.4, 32.2, 30.8, 30.6, 30.5, 25.4, 25.0, 24.7,
14.5 (CH2CH3); HRMS (ESI) calcd for C30H61N2O7S [M + H]
+
593.4194, found 593.4178. Continued elution gave the α anomer
12 (14.5 mg, 20%) as an oil; [α]25D +66.5 (c 1.45, MeOH); δH
(500 MHz, MeOH-d4) 5.28 (d, 1H, J1′,2′ = 3.7 Hz, H1′), 3.81 (m,
1H, H6′a), 3.71 (m, 3H, H3′, 5′ and 6′b), 3.42 (m, 1H, H1 or 2),
3.34 (m, 1H, H4′), 3.23 (m, H1 or 2), 3.08 (m, 1H, H2′ and
SO2CH2), 2.24 (m, 1H, cyclitol), 1.96 (m, 1H, cyclitol),
1.84–1.67 (m, 4H, SO2CH2CH2 and 2H cyclitol), 1.52–1.21
(34H, [CH2]15 and 4H cyclitol), 0.90 (t, 3H, J = 7.0 Hz,
CH2CH3); δC (125 MHz, MeOH-d4) 97.3 (C1′), 81.4 (C1 or 2),
73.2 (C3′ or 5′), 70.4 (C3′ or 4′ or 5′), 70.3 (C3′ or 4′ or 5′), 60.8
(C6′), 56.6 (C1 or 2), 54.9 (C2′), 52.6 (SO2CH2), 32.7, 32.3, 31.6,
29.4, 29.3, 29.2, 29.0, 28.8, 27.8, 24.2, 23.5, 23.3, 22.3, 13.0
(CH2CH3); HRMS (ESI) calcd for C30H61N2O7S [M + H]
+
593.4194, found 593.4181.
trans-2-(4-Methoxybenzyloxy)cyclohexyl acetate 37
Cu(BF4)2·nH2O (42 mg, 0.18 mmol) was dissolved in CH2Cl2
(20 mL) and cyclohexene oxide 36 (1.8 mL, 17.8 mmol) and
4-methoxybenzyl alcohol (10 mL, 80.2 mmol) were added. The
reaction mixture was stirred for 24 h, diluted with water
(20 mL), and the aqueous layer extracted with CH2Cl2 (3 ×
30 mL). The combined organic extracts were washed with
brine, dried over MgSO4, filtered and the solvent was removed
Organic & Biomolecular Chemistry Paper
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in vacuo. The resulting crude monoprotected PMB cyclohexane-
diol22 was used with no further purification in the next step,
whereby it was dissolved in pyridine (7.5 mL), cooled to 0 °C,
before DMAP (3 mg, 0.26 mmol) and acetic anhydride (4.5 mL,
48.0 mmol) were added. The reaction mixture was stirred over-
night at rt, diluted with water (100 mL) and extracted with
EtOAc (3 × 100 mL). The combined organic extracts were
washed with water (100 mL), brine (100 mL), dried over
MgSO4, filtered and the solvent was removed under reduced
pressure. Column chromatography (5 : 1 hexane–Et2O) of the
ensuing residue aﬀorded the oily product 37 (1.37 g, 55%); δH
(500 MHz, CDCl3) 7.24 (d, 2H, J = 8.7 Hz, Ph), 6.86 (d, 2H, J =
8.6 Hz, Ph), 4.83–4.79 (m, 1H, H-1), 4.56–4.49 (2 × d, 2H, J =
11.7 Hz, CH2Ar), 3.80 (s, 3H, OCH3), 3.38–3.33 (m, 1H, H-2),
2.04 (s, 3H, CH3), 2.02–1.98 (m, 2H, H-3a and 6a), 1.70–1.62
(m, 2H, H-4a and 5a), 1.43–1.18 (m, 4H, H-3b, 4b, 5b and 6b);
δC (125 MHz, CDCl3) 170.5 (CvO), 159.1, 131.0, 129.0, 114.0,
113.7, 78.4 (C-2), 75.3 (C-1), 71.0 (CH2Ar), 55.3 (OCH3), 30.0,
29.9, 23.6, 23.3, 21.4 (CH3); HRMS (ESI) calcd for C16H22NaO4
[M + Na]+ 301.1410, found 301.1397.
1-{[trans-2-(Allyloxy)cyclohexyloxy]methyl}-4-methoxybenzene
38
The acetate 37 (938 mg, 3.37 mmol) was dissolved in MeOH
(10 mL) and NaOMe (5.4 M in MeOH, 150 µL) was added and
the solution stirred for 1 h at rt. Afterwards, TLC revealed that
there was still the presence of 37 and, thus, a further aliquot of
NaOMe (5.4 M in MeOH, 100 µL) was added and the reaction
mixture was stirred for an additional 24 h. After which, the
reaction was neutralised with Amberlite IR-120 (H+) ion-
exchange resin, filtered and the crude solution was passed
down a short plug of silica gel (elution with EtOAc) to aﬀord
the known 2-PMB protected alcohol22 as a pale yellow oil
which was used without further purification in the next step.
To a stirred and cooled (0 °C) solution of the alcohol22
(886 mg, 3.75 mmol) in DMF (40 mL) was added NaH (60%
dispersion in mineral oil, 750 mg, 18.7 mmol) and the solu-
tion was stirred for 30 min before allyl bromide (2.92 mL,
22.8 mmol) was added dropwise. The reaction mixture was
stirred under argon for a further 18 h at rt, quenched with
MeOH (50 mL), H2O (250 mL) was added and then the result-
ing solution was extracted with EtOAc (3 × 250 mL). The com-
bined organic extracts were washed with H2O (3 × 250 mL),
brine (250 mL), dried over MgSO4, filtered and the solvent was
removed under reduced pressure. The resulting residue was
passed down a short plug of silica gel (elution with EtOAc)
and, after evaporation to dryness, purified by RBC (elution gra-
dient hexane → 5 : 1 Et2O–hexane) to aﬀord the allyl product
38 (712 mg, 69%) as a clear oil; δH (500 MHz, CDCl3) 7.32 (d,
2H, J = 8.6 Hz, Ph), 6.90 (d, 2H, J = 8.7 Hz, Ph), 6.02–5.94 (m,
1H, CH2CHvCH2), 5.32–5.17 (4 × m, 2H, CH2CHvCH2), 4.63
(dd, 2H, J = 11.4 Hz, CH2Ar), 4.17 (m, 2H, CH2CHvCH2), 3.83
(s, OCH3), 3.37–3.29 (m, 2H, H-1 and 2), 2.03–2.00 (m, 2H,
cyclitol), 1.69–1.67 (m, 2H, cyclitol), 1.39–1.20 (m, 4H, cyclitol);
δC (125 MHz, CDCl3) 159.0, 135.8 (CH2CHvCH2), 131.5, 129.1,
116.1 (CH2CHvCH2), 113.7, 81.0 (C-1 or 2), 80.8 (C-1 or 2),
71.6 (CH2CHvCH2), 71.0 (CH2Ar), 55.3 (OCH3), 30.33, 30.31,
23.59, 23.58; HRMS (ESI) calcd for C17H24NaO3 [M + Na]
+
299.1618, found 299.1607.
2-{[trans-2-((4-Methoxybenzyl)oxy)cyclohexyloxy]methyl}
oxirane 39
Compound 38 (2.22 g, 8.02 mmol) was dissolved in CH2Cl2
(30 mL) and mCPBA (4.15 g, 24.1 mmol) was added and the
reaction mixture stirred for 18 h at rt. Afterwards, the reaction
mixture was washed successively with 10% aq. sodium sulfite
(80 mL), water (100 mL), 10% aq. NaOH (80 mL) and brine
(80 mL). The organic phase was then filtered through cotton
wool and the solvent was removed in vacuo. The crude material
was passed down a short plug of silica gel (further elution
with EtOAc) and evaporated to dryness under reduced
pressure. RBC (elution gradient 1 : 1 → 2 : 1 Et2O–hexane) furn-
ished the epoxide 39 (1.50 g, 64%) as a clear oil; δH (500 MHz,
CDCl3) 7.20 (dd, 2H, J = 8.7 Hz, Ph), 6.77 (d, 2H, J = 8.7 Hz,
Ph), 4.50 (s, 2H, CH2Ar) 3.76–3.40 (5H, OCH3 and 1- or 3-CH2
propyl), 3.25 (m, 2H, H-1 and 2), 3.05 (m, 1H, H-2 propyl),
2.67–2.52 (2H, 1- or 3-CH2 propyl), 1.90 (m, 2H, cyclitol), 1.57
(m, 2H, cyclitol), 1.22–1.06 (m, 4H, cyclitol); δC (125 MHz,
CDCl3) 159.0, 131.4, 131.3, 129.14, 129.08, 113.7, 82.3 (C-1 or
2), 82.1 (C-1 or 2), 80.8 (C-1 or 2), 71.5 (CH2Ar), 71.2 (1- or
3-CH2 propyl), 70.4 (1- or 3-CH2 propyl), 55.2 (OCH3), 51.3 (C-2
propyl), 51.1 (C-2 propyl), 44.44 (1- or 3-CH2 propyl), 44.38
(1- or 3-CH2 propyl), 30.3, 30.20, 30.16, 23.6, 23.5; HRMS (ESI)
calcd for C17H24NaO4 [M + Na]
+ 315.1567, found 315.1553.
3-{[trans-2-((4-Methoxybenzyl)oxy)cyclohexyl]oxy}propane-1,2-
diol 40
To a solution of 39 (1.50 g, 5.13 mmol) in DMSO (56.4 mL) was
added water (10.8 mL) and aq. 0.3 M KOH (2.4 mL). The reac-
tion mixture was heated to 100 °C for 18 h, and then diluted
with water (200 mL) followed by extraction with CH2Cl2 (3 ×
200 mL). The combined organic extracts were washed with
water (100 mL), brine (100 mL), dried over MgSO4, filtered and
the solvent was removed under reduced pressure. The residue,
so obtained, was percolated through a short column of silica
gel (further elution with EtOAc) and the subsequent eluent
was concentrated under reduced pressure. RBC (elution first
with hexane → 6 : 1 EtOAc–hexane) of the residue aﬀorded the
diol 40 (942 mg, 65) as a clear oil; δH (500 MHz, CDCl3) 7.28 (d,
2H, J = 8.6 Hz, Ph), 6.88 (dd, 2H, CH, J = 8.6, Ph), 4.59–4.50
(2H, CH2Ar), 3.82–3.47 (8H, OCH3, H-2 propyl, 1- and 3-CH2
propyl), 3.25 (m, 2H, H-1 and 2), 2.50 (bs, 1H, OH), 2.40 (bs,
1H, OH), 2.11–2.01 (m, 2H, cyclitol), 1.68 (m, 2H, cyclitol),
1.23 (m, 4H, cyclitol); δC (125 MHz, CDCl3) 159.3, 159.2, 130.5,
130.4, 129.5, 129.4, 113.84, 113.83, 83.40 (C-1 or 2), 82.39 (CH,
C-1 or 2), 80.86 (C-1 or 2), 80.78 (C-1 or 2), 72.31 (1- or 3-CH2
propyl), 71.37 (C-2 propyl), 71.03 (1- or 3-CH2 propyl), 70.81
(1- or 3-CH2 propyl), 70.51 (C-2 propyl), 64.20 (1- or 3-CH2
propyl), 63.83 (1- or 3-CH2 propyl), 55.24 (OCH3), 30.75, 30.54,
29.99, 29.93, 23.78, 23.71, 23.69; HRMS (ESI) calcd for
C17H26NaO5 [M + Na]
+ 333.1672, found 333.1678.
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1-[(tert-Butyldiphenylsilyl)oxy]-3-{[trans-2-((4-methoxybenzyl)-
oxy)cyclohexyl]oxy}propan-2-ol 41
To a solution of the primary alcohol 40 (942 mg, 3.34 mmol)
and DIPA (5.8 mL, 3.75 mmol) in CH2Cl2 (5 mL) was added
TBDPSCl (1.04 mL, 4.00 mmol) dropwise followed by DMAP
(5 mg, 0.038 mmol) and the reaction stirred for 24 h at rt.
Afterwards, TLC revealed the presence of the starting material
40; thus an additional aliquot of TBDPSCl (0.521 mL,
2.00 mmol) was added and the reaction mixture was stirred for
a further 3 h, whereafter it was quenched with water (60 mL)
and then extracted with CH2Cl2 (3 × 60 mL). The combined
organic extracts were washed successively with water (100 mL),
brine (50 mL), filtered through cotton wool and the solvent
was removed under reduced pressure. The residue so obtained
was percolated through a short column of silica gel (further
elution with EtOAc) and the subsequent eluent was concen-
trated under reduced pressure. RBC (elution first with hexane
→ 1 : 2 EtOAc–hexane) of the residue aﬀorded the silyl pro-
tected product 41 (1.33 g, 76%) as a pale yellow oil; δH
(500 MHz, CDCl3) 7.68–6.79 (14H, Ph), 4.56–4.44 (m, 2H,
CH2Ar), 3.90–3.51 (8H, OCH3, H-2 propyl, 1- and 3-CH2
propyl), 3.25 (m, 2H, H-1 and 2), 3.12 (bs, 1H, OH), 1.97 (m,
2H, cyclitol), 1.66 (m, 2H, cyclitol), 1.30–1.15 (m, 4H, cyclitol),
1.05 (s, 9H, 3 × CH3); δC (125 MHz, CDCl3) 159.1, 135.6, 135.6,
134.7, 133.5, 133.49, 133.42, 130.9, 130.8, 129.73, 129.72,
129.3, 129.2, 127.74, 127.71, 113.79, 113.77, 82.9 (C-1 or 2),
82.3 (C-1 or 2), 80.7 (C-1 or 2), 80.6 (C-1 or 2), 71.7, 71.6, 71.2,
71.1, 71.0, 70.4, 65.0, 64.8, 55.3, 55.2, 30.6, 30.4, 30.11, 30.06,
29.7, 26.9, 23.69, 23.66, 19.29, 19.28; HRMS (ESI) calcd for
C33H44NaO5Si [M + Na]
+ 571.2856, found 571.2860.
1-[(tert-Butyldiphenylsilyl)oxy]-3-{(trans-2-[(4-methoxybenzyl)-
oxy)cyclohexyl]oxy}propan-2-yl methanesulfonate 42
To the secondary alcohol 41 (1.33 g, 2.54 mmol) in pyridine
(5 mL) was added mesyl chloride (0.63 mL, 8.14 mmol) drop-
wise. The reaction mixture was stirred at room temperature for
24 h and then quenched with saturated NaHCO3 (10 mL) fol-
lowed by extraction with CH2Cl2 (3 × 20 mL). The combined
organic extracts were washed with water (60 mL), brine
(60 mL), filtered through cotton wool and then evaporated to
dryness; whereafter toluene (5 mL) was added and evaporated
therefrom. The resulting oil was passed through a short
column of silica gel (elution with EtOAc) to give a clear yellow
oil after evaporation to dryness under reduced pressure. This
oil was used in the following step without further purification.
However, a small sample of the product (100 mg) was purified
by RBC (1 : 1 Et2O–hexane) to aﬀord a clear, colourless oil of 42
for analytical analyses; δH (500 MHz, CDCl3) 7.60–6.73 (14H,
Ph), 4.70 (m, 1H, H-2 propyl), 4.61–4.35 (m, 2H, CH2Ar),
3.83–3.69 (m, 7H, OCH3, 1- and 3-CH2 propyl), 3.18 (m, 2H,
H-1 and 2), 2.90 (s, 3H, SO2CH3), 1.90 (m, 2H, cyclitol), 1.57
(m, 2H, cyclitol), 1.24–1.08 (m, 4H, cyclitol), 0.98 (s, 9H, 3 ×
CH3); δC (125 MHz, CDCl3) 159.1, 135.6, 135.54, 135.52,
132.94, 132.89, 132.8, 131.1, 131.0, 129.92, 129.90, 129.2,
129.1, 127.9, 113.78, 113.77, 82.5 (CH, CH propyl), 82.4 (CH,
C-1 or 2), 82.1 (CH, C-1 or 2), 81.9 (CH, C-1 or 2), 80.5 (CH,
C9), 71.2, 71.0, 68.9, 68.8, 63.5, 55.3 (OCH3), 38.5 (SO2CH3),
38.4, 30.0, 30.0, 29.8, 26.8, 23.5, 23.4, 19.2; HRMS (ESI) calcd
for C34H46NaO7SSi [M + Na]
+ 649.2626, found 649.2628.
{2-Azido-3-[(trans-2-((4-methoxybenzyl)oxy)cyclohexyl)oxy]-
propoxy} (tert-butyl)diphenylsilane 43
A solution of the mesylate 42 in DMF (10 mL) containing
sodium azide (496 mg, 7.64 mmol) was heated and stirred at
125 °C for 24 h, cooled and then poured into water (40 mL).
The resulting aqueous solution was extracted with CH2Cl2 (3 ×
40 mL) and the combined organic extracts were washed succes-
sively with water (100 mL), brine (100 mL), filtered through
cotton wool and concentrated under reduced pressure. A solu-
tion of the residue in EtOAc was percolated through a short
column of silica gel (elution with EtOAc) and the eluent con-
centrated under reduced pressure. RBC of the residue (elution
first with hexane → 1 : 1 Et2O–hexane) gave the azide 43
(1.30 g, 51%) as a clear oil; δH (500 MHz, CDCl3) 7.62–6.73
(14H, Ph), 4.44 (s, 2H, CH2Ar), 3.71–3.32 (8H, OCH3, H-2
propyl, 1- and 3-CH2 propyl), 3.22 (m, 2H, H-1 and 2), 1.86 (m,
2H, cyclitol), 1.55 (m, 2H, cyclitol), 1.25–1.04 (m, 4H, cyclitol),
0.99 (s, 9H, 3 × CH3); δC (125 MHz, CDCl3) 159.0, 135.9, 135.8,
135.6, 135.3, 134.8, 133.10, 133.06, 131.31, 131.29, 129.8,
129.7, 129.2, 129.12, 129.08, 129.0, 127.8, 127.73, 127.67,
113.74, 113.70, 82.2 (C-1 or 2), 82.0 (C-1 or 2), 80.5 (C-1 or 2),
80.4 (C-1 or 2), 71.5, 71.4, 71.19, 69.5, 69.0, 64.08, 64.05, 63.2,
63.0, 55.3 (OCH3), 30.0, 29.9, 26.9, 26.8, 26.6, 23.43, 23.40,
23.35, 19.2; HRMS (ESI) calcd for C33H43N3NaO4Si [M + Na]
+
596.2915, found 596.2926.
trans-2-{2-Azido-3-[(tert-butyldiphenylsilyl)oxy]propoxy}-
cyclohexanol 44
The PMB derivative 43 (131 mg, 0.240 mmol) was dissolved in
a solution of 1% TFA in CH2Cl2 (8.62 mL). The reaction
mixture was stirred at room temperature for 18 h; whereafter
an additional aliquot of TFA (43 µL) was added because TLC
indicated the presence of the PMB protected starting material
(43). After a further 4 h, TLC revealed the absence of any start-
ing material (43) and the reaction mixture was diluted with
CH2Cl2 (40 mL) and washed with saturated NaHCO3 (40 mL),
water (40 mL), brine (40 mL) and then filtered through cotton
wool. The CH2Cl2 extract was concentrated under reduced
pressure and the residue was percolated through a short
column of silica gel (elution with EtOAc) and concentrated to
dryness under reduced pressure. RBC purification of the
residue (elution first with hexane → 1 : 1 Et2O–hexane)
aﬀorded the alcohol 44 (67 mg, 64%) as a clear oil; δH
(500 MHz, CDCl3) 7.60–7.31 (10H, Ph), 3.74–3.11 (6H, H-1 or 2,
H-2 propyl, 1- and 3-CH2 propyl), 2.99 (m, 1H, H-1 or 2), 2.60
(bd, 1H, OH), 1.96 (m, 2H, cyclitol), 1.65 (m, 2H, cyclitol),
1.23–1.03 (m, 4H, cyclitol), 1.00 (s, 9H, 3 × CH3); δC (125 MHz,
CDCl3) 134.75, 134.58, 134.56, 132.2, 131.91, 131.87, 128.9,
126.81, 126.79, 83.6 (C-1 or 2), 83.5 (C-1 or 2), 72.8, 72.7, 67.3,
67.0, 62.8, 62.7, 62.0, 61.7, 31.02, 30.98, 28.7, 28.1, 25.9, 25.7,
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23.1, 22.9, 18.2; HRMS (ESI) calcd for C25H35N3NaO3Si
[M + Na]+ 476.2340, found 476.2351.
Triethylammonium trans-2-{2-azido-3-[(tert-butyldiphenylsilyl)-
oxy]propoxy}cyclohexyl n-octadecyl phosphate 45
This compound was obtained from the alcohol 44 (280 mg,
0.62 mmol) and the hydrogenphosphonate TEA salt 1815
(537 mg, 1.23 mmol) in the presence of pivaloyl chloride
(0.48 mL, 3.86 mmol) essentially as described for the TEA salt
19. After oxidation with iodine (623 mg, 2.47 mmol) in 9 : 1
pyridine–water followed by the same aqueous workup as
described for 19, column chromatography (CH2Cl2 → 8 : 1
CH2Cl2–MeOH) of the residue aﬀorded the octadecyl phos-
phate TEA salt 45 (276 mg, 50%) as a yellow paste; δH
(500 MHz, CDCl3) 7.63–7.30 (10H, Ph), 4.10 (m, 1H, H-1 or 2),
3.92–3.33 (7H, OCH2, H-2 propyl, 1- and 3-CH2 propyl),
3.28 (m, 1H, H-1 or 2), 3.00 (m, 6H, 3 × CH2CH3),
1.95–1.73 (m, 2H, cyclitol), 1.58–1.46 (m, 4H, OCH2CH2 and
2H cyclitol), 1.35–1.14 (43H, [CH2]15, 3 × CH2CH3 and 4H cycli-
tol), 1.73 (s, 9H, 3 × CH3), 0.80 (t, 3H, CH3, J = 6.8 Hz,
CH2CH3); δC (125 MHz, CDCl3) 134.9, 134.8, 134.6, 132.6,
132.4, 132.1, 132.0, 128.9, 128.8, 126.8, 126.7, 78.8 (C-1 or 2),
78.6 (C-1 or 2), 76.6 (C-1 or 2), 70.8, 70.1, 68.2, 67.7, 65.7, 65.6,
65.5, 63.0, 62.9, 44.5 [N(CH2CH3)3], 30.9, 29.7, 29.6, 29.5, 29.0,
28.70, 28.65, 28.4, 27.2, 26.0, 25.9, 25.7, 24.8, 24.7, 21.7, 21.1,
21.0, 18.2, 14.3 (CH2CH3), 8.5 [N(CH2CH3)3]; δP (202 MHz,
CDCl3) −1.2 (with heteronuclear decoupling); HRMS (ESI)
calcd for C43H71N3O6PSi [M − NEt3 − H]− 784.4885, found
784.4759.
Triethylammonium trans-2-(2-azido-3-hydroxypropoxy)-
cyclohexyl n-octadecyl phosphate 46
Compound 45 (68 mg, 0.077 mmol) was dissolved in THF
(1 mL) and 1.0 M TBAF in THF (153 µL, 0.15 mmol) was
added. The reaction mixture was stirred at rt for 16 h and then
diluted with water (25 mL), extracted CH2Cl2 (3 × 25 mL) and
the combined organic extracts were washed with aq. 1.0 M
TEAB (2 × 10 mL). The organic phase was filtered through
cotton wool, the solvent was removed under reduced pressure
and the resulting residue was purified by column chromato-
graphy (8 : 1 CH2Cl2–MeOH) to aﬀord the alcohol 46 (50 mg,
100%) as a white paste; δH (500 MHz, CDCl3) 4.08–3.33 (8H,
OCH2, H-1 or 2, H-2 propyl, 1- and 3-CH2 propyl), 3.25 (m, 1H,
H-1 or 2), 3.09 (m, 6H, 3 × CH2CH3), 2.14–1.99 (m, 2H, cycli-
tol), 1.66–1.59 (m, 4H, OCH2CH2 and 2H cyclitol), 1.30–1.19
(43H, [CH2]15, 3 × CH2CH3 and 4H cyclitol), 0.88 (t, 3H, CH3,
J = 6.5 Hz, CH2CH3); δC (125 MHz, CDCl3) 81.6 (C-1 or 2), 78.6
(C-1 or 2), 68.6, 68.5, 66.03, 65.99, 62.4, 61.7, 60.9, 60.6, 45.4
[N(CH2CH3)3], 32.2, 32.0, 31.9, 30.8, 30.74, 30.68, 29.73, 29.67,
29.42, 29.38, 25.8, 23.9, 23.8, 23.8, 23.7, 22.7, 14.1 (CH2CH3),
8.5 [N(CH2CH3)3]; δP (202 MHz, CDCl3) −1.02 (with hetero-
nuclear decoupling); HRMS (ESI) calcd for C27H53N3O6P
[M − NEt3 − H]− 546.3677, found 546.3673.
Triethylammonium trans-2-(2-amino-3-hydroxypropoxy)-
cyclohexyl n-octadecyl phosphate 13
Pearlman’s catalyst [10–20% Pd(OH)2 on carbon, 15 mg] was
added to a solution of the azide 46 (45 mg, 0.069 mmol) in
1 : 1 THF–MeOH (10 mL) and the mixture was stirred under a
hydrogen atmosphere at rt for 2 h. Processing as described for
21 gave the amino TEA salt 13 (29 mg, 44%) as a white paste,
which did not require any chromatographic purification; δH
(500 MHz, CDCl3) 4.00–3.31 (8H, OCH2, H-1 or 2, H-2 propyl,
1- and 3-CH2 propyl), 3.10 (m, 1H, H-1 or 2), 3.02 (q, 6H, J =
7.4 Hz, 3 × CH2CH3), 2.04–1.93 (m, 2H, cyclitol), 1.63–1.50 (m,
4H, OCH2CH2 and 2H cyclitol), 1.33–1.05 (43H, [CH2]15, 3 ×
CH2CH3 and 4H cyclitol), 0.81 (t, 3H, CH3, J = 6.7 Hz,
CH2CH3); δC (125 MHz, CDCl3) 81.6 (C-1 or 2), 77.9 (C-1 or 2),
67.1, 65.9, 64.8, 53.2, 44.5 [N(CH2CH3)3], 33.0, 31.8, 30.9, 29.7,
29.6, 29.33, 29.29, 29.0, 28.70, 28.65, 28.43, 28.35, 27.9, 24.9,
24.8, 24.8, 24.7, 23.2, 23.1, 22.8, 22.7, 13.1 (CH2CH3), 7.5
[N(CH2CH3)3]; δP (202 MHz, CDCl3) −0.23 (with heteronuclear
decoupling); HRMS (ESI) calcd for C27H55NO6P [M − NEt3 − H]−
520.3772, found 520.3747.
Biological assays
Materials
The synthesis of 1-D-6-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-
myo-inositol 1-(octadecyl phosphate), (4, α-D-GlcpNH2-IPC18),15
has been described previously. The corresponding N-acetyl
derivate α-D-GlcpNAc-IPC18 (3) was prepared by treatment with
acetic anhydride,13 and the concentration of stock solutions
determined by measurement of the inositol content by
selected ion-monitoring GC-MS.8 Bloodstream form Trypano-
some brucei (variant MITat1.4) were isolated and membranes
(cell-free system) prepared as described previously and stored
at −80 °C.26
Activity assays
Substrate recognition assays were performed using 500 pmol
of α-D-GlcpNAc-PI (1) in incorporation buﬀer (25 mM Tris pH
8.0, 50 mM KCl, 50 mM MnCl2) and varying amounts of
trypanosome cell-free system (0–15 × 106 cell equivalents per
assay) in 96-well plates containing 100 μL final volume, and
incubated at 37 °C for 1 h. The reaction was quenched and the
glycolipids enriched and analyzed by LC-MS/MS as described
below.
Inhibition assays were performed in 96-well plates in
100 μL final volume, with 1% v/v DMSO with or without inhibi-
tor. Trypanosome cell-free system (2.5 × 106 cell equivalents
per assay) in incorporation buﬀer were added to wells contain-
ing 500 pmol α-D-GlcpNAc-IPC18 (3) with or without inhibitor
and incubated at 37 °C for 1 h. The reaction was quenched
and the glycolipids enriched and analyzed by LC-MS/MS as
described below.
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Glycolipid enrichment
Enrichment of glycolipids was performed in a 96-well plate
format. Reactions were quenched by addition of 200 μL of 5%
propan-1-ol, 5 mM NH4OAc, and the glycolipids were bound to
C18 resin (50 mg Isolute Array cartridge), washed three times
with 200 μL 5% propan-1-ol, 5 mM NH4OAc and eluted with
100 μL 40% propan-1-ol, 5 mM NH4OAc into a 96-well collec-
tion plate.
Prior to subsequent analysis, compound 13 was dried
under nitrogen, resuspended in MeOH (100 μL) and any free
amine reacted with excess d6-Ac2O (1.5 μL) in the presence of
pyridine (10 μL) for 15 min. The reaction was quenched with
water (50 μL), dried under nitrogen and resuspended in 100 μL
40% propan-1-ol, 5 mM NH4OAc.
Liquid chromatography – tandem mass spectrometry of
glycolipids
Glycolipids were analyzed by liquid chromatography coupled
to an electrospray tandem mass spectrometer (LC-MS/MS).
Samples (40 μL) were injected directly from a 96-well plate
onto a 10 × 1 mm C18 column (ACE, 5 μM) and then eluted
using a binary gradient of 5–80% propan-1-ol in 5 mM
NH4OAc (Dionex Ultimate 3000). The gradient consisted of
2 min 0% B, 2–4 min 0–100% B, 4–8 min 100%, 8–9 min
100–0% B, 9–10 min 0% B where buﬀer A consisted of 5%
propan-1-ol, 5 mM NH4OAc and buﬀer B 80% propan-1-ol,
5 mM NH4OAc. The glycolipids were analysed on an electro-
spray triple quadrapole mass spectrometer (Micromass
Quattro Ultima) in multiple reaction monitoring mode.
For each pseudodisaccharide analogue (7–12), standards of
the N-acetylated compound and corresponding free amine
were analyzed separately in order to identify unique transitions
for use in subsequent multiple reaction monitoring
experiments (Table 1). The ratio of the integrals for these tran-
sitions was used to calculate the percentage of substrate con-
version to product in a given sample. For compound 13,
standards of the N-acetylated compound and the d3-N-acetyl-
ated form were analyzed separately and found to produce a
common fragment for use in subsequent multiple reaction
monitoring experiments.
For inhibition assays, the turnover of the substrate
α-D-GlcpNAc-IPC18 (3) was used to calculate the percentage of
substrate conversion to product in a given sample.10 Inhibitor
IC50 values were calculated using a four-parameter fit of eight-
point potency curves derived from three independent experi-
ments, and are quoted with a standard deviation.
Trypanosome cell-free system assays
The formation of GPI precursors is monitored by following the
incorporation of [3H]-mannose and then they were analysed
using high-performance liquid chromatography and fluoro-
graphy as described previously.8
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